Clinical Trial

Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit

Study acronym: TAURO-USE2
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures. This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
Trial Details
NCT Number NCT07259421
Lead Sponsor University Hospital, Grenoble
Conditions Taurolidine Lock Solution
Enrollment 45 participants
Start Date 2025-12
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-02